Assessment of Restenotic Neointimal Tissue after Second- or Third-Generation Drug-Eluting Stent Implantation: Evaluation by Histopathology, Optimal Coherence Tomography, and Intravascular Ultrasound

Assessment of Restenotic Neointimal Tissue after Second- or Third-Generation Drug-Eluting Stent Implantation: Evaluation by Histopathology, Optimal Coherence Tomography, and Intravascular Ultrasound - Assessment of Restenotic Neointimal Tissue after Second- or Third-Generation Drug-Eluting Stent Implantation: Evaluation by Histopathology, Optimal Coherence Tomography, and Intravascular Ultrasound

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032068

Enrollment

Registered

2018-04-04

Start date

2018-04-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients who had restenosis after second- or third-generation DES implantation -Restenotic lesion considered appropriate to be treated by DCA -Patients considered appropriate to be used OCT for assessment of restenotic neointimal lesion from the patients background -Patients who have provided written informed consent

Exclusion criteria

Exclusion criteria: Those who were eligible to above criteria can be registered.

Design outcomes

Primary

Measure	Time frame
Histopathological findings, optical coherence tomography (OCT) findings, and intravascular ultrasound(IVUS) findings of restenotic neointimal tissue	—

Countries

Japan

Contacts

Public ContactRiku Arai

The Cardiovascular Institute Cardiology

r-arai@cvi.or.jp03-3408-2151

Outcome results